Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure

Journal of Infectious Diseases

Volumn 179, Issue 1, 1999, Pages 74-82

  Aukrust, Pål ^a   Müller, Fredrik ^b   Lien, Egil ^b   Nordøy, Ingvild ^b   Liabakk, Nina Beate ^b   Kvale, Dag ^b   Espevik, Terje ^b   Frøland, Stig S ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; TUBERCULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032928963     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314572     Document Type: Article

References (45)

1. Agostini J, Zambello R, Trentin L, et al. Expression of TNF receptors by T cells and membrane TNF-α by alveolar macrophages suggest a role for TNF-α in the regulation of the local immune responses in the lung of HIV-1-infected patients. J Immunol 1995;154:2928-38.
2. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxity and tumor necrosis factor production in peripheral blood monocytes from AIDS patients. J Immunol 1988;141:99-104.
3. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor (TNF)-α and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
4. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
5. Godfried MH, van der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictor of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-45.
6. Dalgleish AG. The immune response to HIV: potential for immunotherapy? Immunol Today 1995;16:356-8.
7. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. JAMA 1997;277:145-53.
8. + cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
9. Gulick RM. HIV treatment strategies. JAMA 1998;279:957-9.
10. Cameron QW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-9.
11. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.
12. Fätkenhauer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-6.
13. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with a HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
14. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
15. + lymphocytes during antiretroviral therapy. J Infect Dis 1997;176:1378-82.
16. Starr SE. Immune reconstitution in HIV-infected individuals - what will it take? Immunologist 1998;6:19-22.
17. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-40.
18. Pantaleo G. How immune-based intervention can change HIV therapy. Nature Med 1997;3:483-6.
19. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4 cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
21. Müller F, Rollag H, Gaudernack G, Frøland SS. Impaired in vitro survival of monocytes from patients with HIV infection. Clin Exp Immunol 1990;81:25-30.
22. Gaudernack G, Lundin KE. Rapid immunomagnetic phenotyping of cells. J Immunogenetics 1989;16:169-75.
23. Liabakk NB, Sundan A, Lien E, et al. The release of p55 receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods 1993;163:145-54.
24. Aukrust P, Lien E, Kristoffersen AK, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency - possible immunological and clinical consequences. Blood 1996;87:674-81.
25. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
26. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-45.
27. Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor-α can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 by binding to the CD4 receptor. J Virol 1989;63:4404-8.
28. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-54.
29. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:163-75.
30. + model of chronic infection. J Immunol 1993;150:625-34.
31. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
32. Ito M, Baba M, Mori S, et al. Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro. Biochem Biophys Res Commun 1990;166:1095-101.
33. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997;185:55-64.
34. Maciejewski JP, Weichold FF, Young NS. HIV-1 suppression of hematopoiesis in vitro by envelope glycoprotein and TNF-α. J Immunol 1994;153:4303-10.
35. Johnson N, Parkin JM. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis. Clin Exp Immunol 1999;113:229-34.
36. Müller F, Aukrust P, Lien E, Haug CH, Froland SS. Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J Infect Dis 1998;177:586-94.
37. Munoz C, Carlot J, Fitting C, Misset B, Blériot JP, Cavaillon JM. Dysregulation of in vitro cytokine production in monocytes during sepsis. J Clin Invest 1991;88:1747-54.
38. + lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Med 1998;4:953-6.
39. Champsi JH, Bermudez LE, Young LS. The role of cytokines in mycobacterial infection. Biotherapy 1994;7:187-93.
40. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351:252-5.
41. Mulligham CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-α polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997;159:6236-41.
42. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Molec Med 1995;1:384-97.
43. Dezube BJ, Lederman MM, Spritzler JG, et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. J Infect Dis 1995;171:1628-32.
44. Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-α by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996;174:63-8.
45. Aukrust P, Hestdal K, Lien E, et al. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor α activity in patients with human immunodeficiency virus type 1 infection. J Infect Dis 1997;176:913-23.